Embedded Files
Engineering next-generation RNA therapeutics inspired by extracellular vesicles
Introduction
Scientific contributions to cancer biology and RNA-based therapeutics
Scientific contributions to cancer biology and RNA-based therapeutics
Our research has contributed to the understanding of cancer signaling networks, extracellular vesicle biology and the development of innovative RNA-based therapeutic strategies.
Our research has contributed to the understanding of cancer signaling networks, extracellular vesicle biology and the development of innovative RNA-based therapeutic strategies.
Through multidisciplinary approaches combining molecular biology, functional genomics and translational research, we aim to uncover new therapeutic opportunities against aggressive cancers.
Through multidisciplinary approaches combining molecular biology, functional genomics and translational research, we aim to uncover new therapeutic opportunities against aggressive cancers.
Featured Publication
A combinatorial RNA therapeutic strategy inspired by extracellular vesicles
A combinatorial RNA therapeutic strategy inspired by extracellular vesicles
Our recent study published in Molecular Therapy demonstrates that a defined combination of 15 microRNAs reproduces the anti-tumoral activity of NFAT3-regulated extracellular vesicles.
This work establishes EV-inspired combinatorial RNA therapeutics as a new strategy to target multiple cancer-driving pathways simultaneously.
Featured publication
Tossou et al.
Molecular Therapy (2026)
A combinatorial EVs-miRNA signature mediates the anti-tumoral activity of NFAT3-regulated extracellular vesicles in aggressive cancers
Research Themes
Extracellular Vesicles and Cancer Communication
Extracellular Vesicles and Cancer Communication
A combinatorial EVs-miRNA signature mediates the anti-tumoral activity of NFAT3-regulated extracellular vesicles in aggressive cancers.
Tossou G, Ourari N, Ralu M, Montanede A, Guaddachi F, Beher B, Paul M, Ouanounou E, le Bras M, Brunet S, Lehmann-Che J, Jauliac S.
Mol Ther. 2026 Jul 30:S1525-0016(26)00673-8. doi: 10.1016/j.ymthe.2026.07.052. Online ahead of print. Read the article
Development of extracellular vesicle-based medicinal products: A position paper of the group "Extracellular Vesicle translatiOn to clinicaL perspectiVEs - EVOLVE France".
Silva AKA, Morille M, Piffoux M, Arumugam S, Mauduit P, Larghero J, Bianchi A, Aubertin K, Blanc-Brude O, Noël D, Velot E, Ravel C, Elie-Caille C, Sebbagh A, Boulanger C, Wilhelm C, Rahmi G, Raymond-Letron I, Cherukula K, Montier T, Martinaud C, Bach JM, Favre-Bulle O, Spadavecchia J, Jorgensen C, Menasché P, Aussel C, Chopineau J, Mosser M, Ullah M, Sailliet N, Luciani N, Mathieu N, Rautou PE, Brouard S, Boireau W, Jauliac S, Dedier M, Trouvin JH, Gazeau F, Trouillas M, Peltzer J, Monsel A, Banzet S.
Adv Drug Deliv Rev. 2021 Dec;179:114001. doi: 10.1016/j.addr.2021.114001. Epub 2021 Oct 19. Read the article
Extracellular vesicles produced by NFAT3-expressing cells hinder tumor growth and metastatic dissemination.
de Camargo LCB, Guaddachi F, Bergerat D, Ourari N, Coillard L, Parietti V, Le Bras M, Lehmann-Che J, Jauliac S.
Sci Rep. 2020 Jun 2;10(1):8964. doi: 10.1038/s41598-020-65844-x. Read the article
RNA Biology and Therapeutic Strategies
RNA Biology and Therapeutic Strategies
A combinatorial EVs-miRNA signature mediates the anti-tumoral activity of NFAT3-regulated extracellular vesicles in aggressive cancers.
Tossou G, Ourari N, Ralu M, Montanede A, Guaddachi F, Beher B, Paul M, Ouanounou E, le Bras M, Brunet S, Lehmann-Che J, Jauliac S.
Mol Ther. 2026 Jul 30:S1525-0016(26)00673-8. doi: 10.1016/j.ymthe.2026.07.052. Online ahead of print. Read the article
NFAT Cancer Signaling Networks
NFAT Cancer Signaling Networks
The NFAT3/RERG Complex in Luminal Breast Cancers Is Required to Inhibit Cell Invasion and May Be Correlated With an Absence of Axillary Lymph Nodes Colonization.
Coillard L, Guaddachi F, Ralu M, Brabencova E, Garbar C, Bensussan A, Le Bras M, Lehmann-Che J, Jauliac S.
Front Oncol. 2022 Jun 30;12:804868. doi: 10.3389/fonc.2022.804868. eCollection 2022. Read the article
Lipocalin 2, the TNF-like receptor TWEAKR and its ligand TWEAK act downstream of NFAT1 to regulate breast cancer cell invasion.
Gaudineau B, Fougère M, Guaddachi F, Lemoine F, de la Grange P, Jauliac S.
J Cell Sci. 2012 Oct 1;125(Pt 19):4475-86. doi: 10.1242/jcs.099879. Epub 2012 Jul 5. Read the article
Dual role of the ddx5/ddx17 RNA helicases in the control of the pro-migratory NFAT5 transcription factor.
Germann S, Gratadou L, Zonta E, Dardenne E, Gaudineau B, Fougère M, Samaan S, Dutertre M, Jauliac S, Auboeuf D.
Oncogene. 2012 Oct 18;31(42):4536-49. doi: 10.1038/onc.2011.618. Epub 2012 Jan 23. Read the article
NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene.
Fougère M, Gaudineau B, Barbier J, Guaddachi F, Feugeas JP, Auboeuf D, Jauliac S.
Oncogene. 2010 Apr 15;29(15):2292-301. doi: 10.1038/onc.2009.499. Epub 2010 Jan 25. Read the article
Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT
Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A.
Mol Cell. 2005 Nov 23;20(4):539-50. doi: 10.1016/j.molcel.2005.10.033. Read the article
The role of NFAT transcription factors in integrin-mediated carcinoma invasion.
Jauliac S, López-Rodriguez C, Shaw LM, Brown LF, Rao A, Toker A.
Nat Cell Biol. 2002 Jul;4(7):540-4. doi: 10.1038/ncb816. Read the article
Page updated
Google Sites
Report abuse